Review on: BRD4 inhibitors for anticancer research

Treatment of cancer is now in a phase of new possibilities, and with the targeted therapy, the advancement of the therapy is considered as the next generation of cancer treatment. The risk of life with cancer is enormous, and the treatment methods available are inefficient. The Bromodomain and extra terminal (BET) protein inhibition is the process where a small molecule inhibits the BET proteins to block the action of these proteins and the transcription of oncogenes. The BET family proteins have emerged as valued targets in developing novel therapeutic agents for human diseases like cancer, HIV infection, inflammation, cardiac arrest, and diabetes. Among all other BET family members (BRD2, BRD3, BRD4 AND BRDT), BRD4 is the most specific target in cancer, AML, MM, Burkitt's Lymphoma and others. This review work also discussed our novel-designed experimental ligands, which exhibit better binding and docking scores than JQ1 and LY2. The toxicity of JQ1 makes it required to design and develop new inhibitors for BRD4, and the anticancer research work has produced many inhibitors in various stages of clinical trials. We will investigate the important ones in this work to better understand these potential anticancer drugs.